The ASX Small Cap Wrap lands on Livewire: insights on XRF, Monash IVF, Cuscal & PWR as reporting season wraps up.

Reporting season always throws up some winners and losers. We look at some of the August trends, and how key holdings have performed.

FY25 numbers looked mixed, but record contracts and faster billing growth set the stage for upside.

Spotting the winners and losers from an emerging investment theme is not always straightforward. What looks like sure things at the outset can end up letting you down,...

DroneShield posts record 1H25 as it shifts toward a SaaS-like model, leans on AI, and expands manufacturing hubs in Europe and the US.

NVIDIA is reaffirming its dominant position in the AI infrastructure space, with continued strong demand for its products despite headwinds.

Bank funding is relying more on bank bonds and local investment and pension funds have grown in importance as buyers of these bonds.

The top-tipped ETFs of 2025 show that growth isn’t the only flavour driving returns — value and dividends have been the real stars so far.

AI will accelerate wealth winners in markets, as capitalism falls to mega-cap tech and online landlords create more wealth for investors.

Inflecting profitability and cashflow discipline are creating selective ASX opportunities. Luke Laretive explains where value emerges.

The strong outlook is driving investor interest and M&A activity among juniors, as shown by Coda’s rise and the PolarX-Northern Star deal.

The respected chief market strategist on where he sees the global winners and losers and why investors need to expect more volatility.

Markets looked past earnings to guidance. From rates to margins, these lessons reveal how to navigate the cycle ahead.

Ben Rundle and Joe McCarthy spotlight the reporting season quiet achievers and their top overlooked ASX picks.

Investors were more than eager to snap up shares in Australia's largest dealership group after impressive H1 results.

Australia’s inflation re-accelerates, testing the RBA’s credibility as rising CPI and core prices challenge dovish policy bets.

Medibank's 40% year-to-date rally slightly unraveled on Thursday, despite the company reporting a solid set of numbers for FY25.

It's been a strong year for the Australian stock market. How did your picks stack up?